EXPRESSION OF P FALCIPARUM LSA-1 SUBUNITS

描述：（改编自申请人的摘要）疟疾是一种热带疾病， 寄生虫病是一个重大的健康威胁。每年约有 全世界有5亿人感染，200万至300万人死亡。有一个 控制这种疾病的蔓延是非常必要的。最近，发展 疟疾疫苗集中于使用重组DNA技术。的 包括红细胞前抗原，例如肝阶段抗原-1 （LSA-1），在开发成功的多组分 疟疾疫苗到目前为止，大多数开发基于LSA-1的疫苗的努力都是 集中于使用确定的肽序列。第一阶段研究将测试 有效表达截短形式疟原虫的可行性 恶性疟原虫LSA-1抗原。这些重组亚基具有潜力， 提供比测试的合成肽更广泛的免疫应答。的 为这项研究提出的表达系统已被证明表达高 重组蛋白水平，包括疟疾红细胞阶段疫苗 候选抗原成功表达高水平的肝脏分期 具有适当抗原性和免疫原性的候选疫苗抗原 这些特性可能有助于开发一种安全、有效和 成本效益高的疟疾疫苗。 拟定商业应用： 疟疾对健康构成重大威胁。每年约有5亿人感染，1至2百万人死亡。目前还没有疟疾疫苗。这项拟议中的研究将测试表达和分泌针对疫苗开发的疟疾亚单位的可行性。高水平的该亚基的成功表达可有助于开发安全、有效和具有成本效益的疟疾疫苗。

DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a tropical parasitic disease that is a significant health threat. Each year, approximately 500 million people become infected and 2 to 3 million die worldwide. There is a great need to control the spread of this disease. Recently, the development of malaria vaccines has focused on the use of recombinant DNA technology. The inclusion of pre-erythrocytic antigens, such as the liver stage antigen-1 (LSA-1), is important in the development of a successful multi-component malaria vaccine. To date, most efforts to develop LSA-1-based vaccines have focused on the use of defined peptide sequences. Phase I research will test the feasibility of efficiently expressing truncated forms of the Plasmodium falciparum LSA-1 antigen. These recombinant subunits have the potential to provide a broader immune response than the synthetic peptides tested. The expression system proposed for this research has been shown to express high levels of recombinant proteins, including a malaria erythrocyte stage vaccine candidate antigen. The successful expression of high levels of a liver stage candidate vaccine antigen with appropriate antigenic and immunogenic characteristics could contribute to the development of a safe, efficacious and cost effective vaccine for malaria. PROPOSED COMMERCIAL APPLICATION: Malaria poses a significant health threat. Annually, approximately 500 million people become infected and 1 to 2 million die. Currently, there is no vaccine for malaria. The proposed research will test the feasibility of expressing and secreting a malaria subunit targeted for vaccine development. Successful expression of high levels of this subunit could contribute to the development of a safe, efficacious and cost effective malaria vaccine.